Company: STAA
Filing Date: 2025-08-05
Form Type: DEFA14A
Source: 0001193125-25-173106
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-08-05
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☐ | Definitive Additional Materials |

| ☒ | Soliciting Material under §240.14a-12 |

STAAR SURGICAL COMPANY (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 
 14a-6(i)(1) and 0-11                                                           |

STAAR Surgical Company (the “Company”) sent the following courtesy email to certain investors and analysts on August 4, 2025: Subject: STAAR Surgical Enters Definitive Agreement to Be Acquired by Alcon for $28 Per Share I’m writing with some exciting news. A few moments ago, we announced that STAAR Surgical has entered into a definitive agreement to be acquired by Alcon for $28 per share in cash. A copy of the press release is attached. Highlights of the transaction include the following:

| • |     | Provides immediate and certain value at a significant premium, value that exceeds what we believe could be 
 achieved under STAAR’s standalone strategy.                                                                |

| • |     | 59% premium to STAAR’s 90-day Volume Weighted Average Price (VWAP) |

| • |     | Transaction is expected to close in six to 12 months, subject to customary closing conditions and approvals, 
 including approval by STAAR shareholders.                                                                    |

| • |     | Transaction is not subject to a financing condition. |

| • |     | The Board of STAAR has unanimously approved the transaction. |

We value your investment and support. Additional Information About the Merger and Where to Find It This communication relates to the proposed transaction involving the Company. In connection